Type 2 diabetes is curable in the majority of patients for whom the disease is less than six years old. This is no longer fringe science. It is published, replicated, mechanistically explained — and almost never discussed at your doctor’s appointment.
If you’ve been told that type 2 diabetes is a chronic, progressive disease that will require lifelong medication, you were told something the published literature no longer supports.
This is the most important sentence in this entire series, so I want to land it again with the specificity it deserves:
Type 2 diabetes is reversible in the majority of patients diagnosed in the last six years. The remission is achievable through dietary intervention alone, without bariatric surgery, without pharmaceuticals, without exotic interventions. The mechanism of reversal has been documented through MRI imaging studies across multiple research groups. The trial data is replicated and substantial. The medical establishment has the evidence. They have not, in any meaningful way, built the patient conversation around it.
This is the post that closes that gap. We’re going to walk through the trial data — DiRECT, ReTUNE, Virta — that proves the disease can be reversed. We’re going to look at the mechanism: what actually happens in the liver, pancreas, and beta cells during remission. We’re going to talk about the six-year window after diagnosis when remission rates are highest. And we’re going to land on the practical framework — diet, exercise, time-restricted eating, sleep, stress — that you or your clients can use to actually do this.
Type 2 diabetes can be cured. Most of the patients who have it can cure it. The work that follows is how.
The DiRECT trial — and what it proved
The first major trial to prove type 2 diabetes was a reversible disease was published in The Lancet in 2018. It was called DiRECT — the Diabetes Remission Clinical Trial — and it was led by Professor Roy Taylor’s team at Newcastle University, the same researchers who had proposed the Twin Cycle Hypothesis a decade earlier.
The trial enrolled 306 patients, with 298 in the intention-to-treat population (149 per group) — adults with type 2 diabetes of less than six years’ duration. None of them had advanced complications. None of them were on insulin. They were the population that the standard guidelines described as needing “lifelong management.”
The intervention was straightforward and deliberately low-tech:
Step 1 — Stop the diabetes medications. Before the dietary intervention began, patients in the intervention arm were taken off their antidiabetic medications. Their blood pressure medications were also reviewed and reduced or stopped where possible. This alone tells you something about the framework being tested — Taylor’s team did not consider the medications central to the patient’s outcome.
Step 2 — A 12 to 20-week formula diet. Patients consumed 825 to 853 calories per day of nutritionally complete liquid formula. This was the most aggressive part of the intervention — a sustained, structured, very-low-calorie diet designed to rapidly mobilize ectopic fat from the liver and pancreas.
Step 3 — Structured food reintroduction over 2 to 8 weeks. Patients gradually returned to whole foods, with structured guidance on portion size, macronutrient composition, and eating pattern.
Step 4 — Ongoing weight maintenance support. Patients received continued counseling and support to maintain their lower body weight long-term.
The results, published at the 1-year follow-up:
- 46% of the intervention group achieved remission of type 2 diabetes — defined as HbA1c below 6.5% without diabetes medications.
- 86% of participants who lost 15kg (33 pounds) or more achieved remission (31 of 36 participants in this subgroup).
- 73% of participants who lost 10kg (22 pounds) or more achieved remission (47 of 64 participants in this subgroup).
At the 2-year follow-up, 36% of the intervention group remained in remission — meaning more than a third of patients with type 2 diabetes were, two years later, no longer diabetic, on no medications, and showing normal glucose metabolism.
By the 5-year follow-up, 13% of the intervention group was still in remission. The number had declined as some participants regained weight. But of those who maintained remission at 2 years, 26% were still in remission at 5 years. And — critically — the intervention group had less than half the rate of serious adverse events of the control group over the entire 5-year follow-up period: 4.8 events per 100 patient-years versus 10.2 events per 100 patient-years.
Even when remission wasn’t sustained, the health outcomes were dramatically better in patients who had gone through the intervention.
This was the trial that broke the “chronic and progressive” framework. The medical literature had said, for thirty years, that type 2 diabetes was a one-way disease — you got it, you managed it, you got worse. DiRECT showed that for nearly half of patients within the first six years of diagnosis, the disease could be put into clinical remission through dietary intervention alone. The Lancet published it. The NHS in the UK began rolling it out as an actual treatment pathway.
The American medical system has not done the same.
The ReTUNE trial — when “normal weight” diabetics get the same result
The first criticism of DiRECT was that it had only tested the intervention in overweight or obese patients. The intervention worked, the critics said, but only for people with a lot of weight to lose. People with “normal” body composition who developed type 2 diabetes were presumably a different population with a different underlying disease.
Taylor’s team answered that question with ReTUNE, published in 2023.
ReTUNE enrolled type 2 diabetics with BMI between 21 and 27 — the “normal weight” or “overweight” range that mainstream medicine assumed represented a separate disease phenotype. The same intervention protocol from DiRECT was applied: medication withdrawal, formula diet for 12 to 20 weeks, food reintroduction, weight maintenance support.
The result was identical to DiRECT.
MRI scans demonstrated significant reductions in liver and pancreatic fat. Liver fat dropped from an average of 4.0% to 1.6% — bringing the participants into the range of healthy non-diabetic controls. Pancreas fat reduced from 6.1% to 5.0%. And — most importantly — 70% of participants achieved type 2 diabetes remission, with an average weight loss of just 6.5%.
The ReTUNE finding settles the personal fat threshold argument completely. People with “normal” BMIs who develop type 2 diabetes have excess fat in their liver and pancreas — they have just exceeded their personal threshold at a lower scale weight than the average diabetic. Remove the ectopic fat through dietary intervention, and the disease resolves regardless of starting body composition.
This means the “I’m not overweight, so I can’t reverse it” objection is wrong. The “I’m not overweight, so this doesn’t apply to me” framing is also wrong. The variable was never scale weight or BMI. It was always ectopic fat. ReTUNE confirmed it.
Virta Health — the ketogenic path to the same destination
DiRECT and ReTUNE used calorie restriction as the primary mechanism for emptying liver and pancreas fat. There is a second approach, structurally different but mechanistically related, that produces similar remission outcomes through a different metabolic route.
Virta Health is a US-based clinical program that uses a sustained, very-low-carbohydrate ketogenic diet to treat type 2 diabetes. The protocol involves daily nutritional ketosis (blood ketones above 0.5 mmol/L), structured macronutrient targets, continuous remote monitoring through a physician-supervised program, and gradual medication deprescribing as glucose normalizes.
Virta’s published clinical trial results: 60% of patients achieved type 2 diabetes reversal at 1 year, and 55% sustained reversal at 2 years. It’s worth noting Virta defines “reversal” as HbA1c below 6.5% off all glucose-lowering medications except metformin. The international consensus definition of “remission” used by DiRECT requires complete medication freedom including metformin. Both metrics matter, but they’re not the same thing — and any honest reading of Virta’s data needs that distinction explicit.
Their 5-year data, published in Diabetes Research and Clinical Practice in 2024, showed that 20% of the 5-year completers (n=120) achieved full remission, with sustained remission over three years in 15.8% and four years in 12.5%. Important context: those 120 patients represented 46% of the original 262 enrolled. Critics calculating from original enrollment cite a lower number. Both ways of reporting are valid — what matters is that real patients achieved sustained, drug-free remission of type 2 diabetes through dietary intervention alone, and the effect persisted over years.
The key insight from Virta is that the dietary approach doesn’t have to be calorie restriction. Sustained carbohydrate restriction produces a different metabolic state — one where the body shifts to using fat as the primary fuel — but the downstream effect on liver fat, pancreatic fat, and glycemic control is similar. The patient’s liver empties of glycogen, then of fat, as it shifts to producing ketones from fat substrate. The same underlying ectopic fat mobilization that drives DiRECT outcomes drives Virta outcomes.
Two different dietary mechanisms. Same destination. The variable that matters is the removal of the dietary driver (refined carbohydrates, fructose, ultra-processed foods) and the creation of a metabolic environment in which the body mobilizes its excess fat reserves. Whether that’s achieved through calorie restriction, carbohydrate restriction, or some combination is — at the patient level — a question of preference and sustainability rather than mechanism.
The mechanism of reversal: what actually happens in the body
This is the part of the research that deserves the most attention, because it’s mechanistically clean and explains why the reversal is so consistent across different dietary approaches.
Week 1-2 — Glycemic normalization. This is the part that surprises most patients and most coaches. Blood glucose normalizes within days to weeks of starting a structured dietary intervention, before significant weight loss has occurred. The mechanism is liver glycogen depletion and reduced hepatic glucose production. The fatty, insulin-resistant liver has been overproducing glucose for years. When the dietary input that’s been overloading it stops, the overproduction stops. Glucose normalizes. For patients on insulin, sulfonylureas, or other glucose-lowering medications, this rapid glycemic improvement creates a real risk of hypoglycemia if doses aren’t adjusted in time. Medication tapering must be coordinated with the prescribing physician — usually within the first 1-2 weeks. This is not optional.
Week 2-8 — Liver fat clearance. As caloric or carbohydrate restriction continues, the liver mobilizes its stored fat as fuel. Liver fat percentages drop dramatically — from typical diabetic baseline of 10 to 20% to under 5% within two months. Hepatic insulin sensitivity improves substantially during this phase. The first cycle of the Twin Cycle is closing.
Month 2-6 — Pancreas fat clearance. This is the slower phase. The pancreas does not mobilize its fat as rapidly as the liver. But as the systemic environment changes — VLDL particles decline because the fatty liver is no longer overproducing them, inflammation reduces, insulin demand drops — the pancreas slowly clears its excess fat. Beta cell function begins to recover. Endogenous insulin production normalizes. The second cycle of the Twin Cycle is closing.
Month 6-12 — Sustained remission. For patients who maintain the dietary changes, HbA1c remains in the normal range without medications. Liver fat stays low. Pancreas fat stays low. The disease is, by any reasonable clinical definition, in remission.
The critical timing pattern: glycemic improvement comes before weight loss, and beta cell recovery comes after liver fat clearance. The disease doesn’t reverse all at once. It reverses in a sequence that reflects the underlying pathology — first the liver, then the pancreas, with glucose normalizing alongside the liver phase and beta cell function recovering during the pancreas phase.
The implication for patients: you don’t have to lose a specific amount of weight to start seeing benefit. The glycemic normalization comes early, often before the scale moves significantly. The full remission requires sustaining the intervention long enough to clear pancreatic fat. But the early signal — glucose dropping, medications becoming unnecessary — appears within the first few weeks for most patients.
The six-year window
The strongest predictor of whether a patient with type 2 diabetes can achieve remission is duration of disease at the time of intervention.
The DiRECT trial specifically enrolled patients with T2D of less than six years’ duration. The remission rates in that population were striking — 46% at 1 year, 73% in those who lost more than 10kg, 86% in those who lost more than 15kg. Subsequent research has confirmed that remission rates drop substantially as disease duration increases. Patients diagnosed within the last 1-2 years have the highest remission rates. Patients diagnosed 3-6 years ago have lower but still substantial rates. Patients beyond 8-10 years of diagnosis have much lower remission rates, although significant improvements in glycemic control and medication burden are still achievable.
The biological reason is straightforward: beta cell apoptosis accumulates over time. The longer the pancreas has been under metabolic stress, the more beta cells have died, and the less reserve capacity remains. At some point, the pancreas’s insulin-producing reserve drops below the threshold needed for full remission, even with complete dietary intervention. The patient can dramatically improve. They can reduce or eliminate medications. They can avoid further complications. But the full restoration to a “no diabetes” status may not be achievable.
The clinical implication is urgent. Anyone newly diagnosed with type 2 diabetes — within the last six years — is in the window where remission is most likely. Anyone whose primary care doctor is treating them with “let’s increase the metformin and see what happens” is squandering that window. Time is the variable that converts a curable disease into a chronic one.
If you or someone you love has been diagnosed within the last six years, this is the most important fact in this entire series. The window matters. The earlier the intervention, the higher the remission rate. Delay is not neutral.
The practical framework — what to actually do
Trial data is great. Mechanism explanations are useful. Without an actionable framework, none of it changes anyone’s life.
Here is the framework, distilled from the DiRECT, ReTUNE, and Virta protocols and from coaching dozens of clients through metabolic dysfunction.
1. Remove the dietary drivers. This is non-negotiable. The Twin Cycle is driven by hepatic fat accumulation, and the hepatic fat is driven primarily by fructose and refined carbohydrates delivered through ultra-processed foods. The intervention starts with removing those inputs.
In practice:
- Eliminate sugar-sweetened beverages completely (soda, sweet coffee drinks, sweet tea, fruit juice, sports drinks)
- Eliminate ultra-processed foods (anything with an ingredient list longer than five items, anything with high-fructose corn syrup, anything that comes in a wrapper designed for shelf life)
- Restrict refined carbohydrates (white bread, pasta, pastries, packaged snacks)
- Limit added sugars from any source
- Keep whole fruit in moderation (1-2 servings per day, paired with protein or fat to slow absorption)
2. Choose the approach that works for you. Both calorie restriction (DiRECT-style) and sustained carbohydrate restriction (Virta-style) can drive remission. The right approach depends on the patient’s psychology, lifestyle, and adherence pattern. For some, structured calorie counting and meal replacement is sustainable. For others, defining macronutrient ratios and eating to satiety in a low-carb framework is more sustainable. The mechanism is similar. The adherence pattern is what determines outcomes.
3. Resistance training is non-negotiable. This is where my coaching practice and the published literature converge most strongly. Skeletal muscle is the largest glucose disposal organ in the body. A single bout of resistance training increases insulin sensitivity for 24 to 48 hours. Sustained resistance training preserves and builds the muscle mass that protects against the metabolic decline that drives this disease.
The protocol I use with clients: full-body resistance training three times per week minimum, with at least 8-12 working sets per major muscle group per session, progressive overload tracked over time, and adequate protein intake (1 gram per pound of target body weight, minimum) to support muscle protein synthesis.
This is the missing piece in almost every standard T2D treatment pathway. Patients are told to “exercise more.” They are rarely coached on the specific kind of training that actually moves the disease.
4. Walk after meals. The simplest intervention with the highest practical return. A 10 to 15-minute walk after each meal lowers post-meal glucose response by 20 to 30%. Over the course of a day, this dramatically reduces the cumulative glucose and insulin load on the system. It costs nothing. It requires no equipment. It works at any fitness level.
5. Address the accelerants. Sleep at least seven hours per night. Manage chronic stress through whatever tools work for the patient (meditation, therapy, journaling, reduced commitments, increased recovery time). Reduce sitting time during the day — set timers, take walking calls, install standing options where possible. These are not optional add-ons. They are part of the same metabolic environment that drives the disease.
6. Consider time-restricted eating. A 12 to 14-hour overnight fast — eating between approximately 8 AM and 6 PM, or 10 AM and 8 PM, or some similar window — gives the liver time to empty glycogen between meals and reduces the cumulative insulin exposure throughout the day. This is a tool, not a requirement. For patients who find structured eating windows sustainable, it accelerates the metabolic improvements. For patients who struggle with it, the other framework elements are sufficient.
7. Track the markers. Get a baseline fasting insulin, HbA1c, fasting glucose, hsCRP, lipid panel, and — if possible — an ApoB. Repeat every 3 to 6 months as the intervention progresses. The numbers will move quickly in the first 3 months and then more gradually over the next 6-12 months. Tracking them is what creates the feedback loop that sustains the behavioral changes.
8. Coordinate with your medical team. Most patients on this protocol will need to reduce or eliminate diabetes medications within the first 4 to 8 weeks. This needs to happen under medical supervision. Sudden cessation of certain medications can be dangerous, and the dose adjustments need to be calibrated to the patient’s glycemic response. Find a physician who is willing to work with you on a remission protocol rather than a management protocol. They exist. They are not the majority. But they exist.
One nuance worth flagging before we close: not all diabetes medications are mechanistically equal. Metformin manages hepatic glucose production without addressing ectopic fat. But some of the newer drug classes — particularly the SGLT2 inhibitors (Jardiance, Farxiga) and the GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) — do produce measurable improvements in liver and pancreas fat beyond what metformin can offer. The semaglutide phase 3 MASH trial published in NEJM in 2025 demonstrated significant resolution of steatohepatitis and improvement in liver fibrosis, leading to FDA approval for fatty liver disease in August 2025. That is real progress, and the honest accounting of each drug class deserves its own dedicated treatment. We’ll handle that in a follow-on series. The relevant point for this post is that even these newer drugs work largely by recreating the metabolic state that dietary intervention creates — pharmaceutically rather than behaviorally. The durability problem is what distinguishes them from the lifestyle path, and that’s the next section.
What “cure” actually means
A note on terminology, because the medical literature is precise about this and the patient conversation often isn’t.
Remission is the term used in the trials. It means HbA1c below 6.5% without antidiabetic medications, sustained over a defined period. Different research groups use slightly different definitions (some require below 6.0%, some require longer durations), but the core concept is consistent: the disease is no longer clinically detectable, and the patient is no longer on medication for it.
Cure is the word patients use, and it’s the right word in everyday language. The disease has gone into clinical remission. The patient is no longer diabetic by any standard test. They are not on diabetes medication. They have, by any reasonable definition, stopped having the disease.
But there is a caveat that matters. The underlying susceptibility to type 2 diabetes does not disappear. The patient who achieved remission still has the genetic profile, the personal fat threshold, and the metabolic history that allowed the disease to develop. If they return to the dietary and lifestyle pattern that produced the disease in the first place, the disease will return. The DiRECT 5-year data shows this clearly — among patients who regained the weight they lost, remission rates declined sharply.
So “cure” is accurate as a description of the patient’s current state. But it is not accurate as a description of permanence. The cure is sustained as long as the conditions that produced the disease are not restored. Most patients who achieve remission find that the sustained metabolic improvement, the reduced medication burden, and the improved energy and body composition create their own incentive to maintain the dietary changes. The framework becomes the new normal rather than a temporary intervention.
This is exactly the model my coaching practice has been built around. The work isn’t a 12-week intervention followed by a return to baseline. The work is a permanent change in how the patient eats, moves, sleeps, and lives. The medications go away. The disease goes away. The dietary framework stays.
This is the actual difference between lifestyle-driven remission and pharmaceutical glucose management — and it’s the line that separates the cure conversation from the management conversation. The drugs produce results while you take them. The lifestyle changes produce results that persist as long as the changes do. More importantly, the underlying disease state — the ectopic fat in the liver and pancreas, the beta cell dysfunction, the systemic inflammation — actually resolves with sustained lifestyle intervention. With pharmaceutical management, the glucose number normalizes while the underlying pathology continues. Two completely different outcomes, often produced by interventions that look superficially similar on a 6-month HbA1c report.
Where this series leaves you
Four posts. Tens of thousands of words. One argument:
Type 2 diabetes is not a chronic and progressive disease for the majority of patients. It is a metabolic dysfunction with a clear mechanism, a reversible course, and a documented pathway out.
The pathway requires understanding what’s actually happening in your body — the hyperinsulinemia, the ectopic fat accumulation, the beta cell stress, the cardiovascular and neurological consequences. It requires recognizing that the standard screening missed the disease for years before your diagnosis. It requires understanding that the drugs being prescribed manage glucose but don’t address the underlying pathology. And it requires actually doing the dietary, exercise, sleep, and stress work that the trial data shows resolves the disease in the majority of patients diagnosed in the last six years.
If you are newly diagnosed, you are in the window where remission is most likely. The work is in front of you. The framework is here. The medical establishment is not going to volunteer this conversation. You will need to bring it.
If you have a family member or client who is newly diagnosed, the same is true. The most consequential thing you can do for them is send them this series and help them advocate for a remission-focused treatment plan rather than a lifelong-management plan.
If you are already deep into the disease — 10+ years post-diagnosis, on insulin, with complications already developing — you may not be able to fully reverse the disease. But you can almost certainly improve your glycemic control, reduce your medication burden, slow your progression, and improve your quality of life and your long-term prognosis. The framework still applies. The remission rate is lower. The benefit is still substantial.
And if you’re already on a statin or any other long-term medication for the metabolic conditions that travel with T2D — high cholesterol, hypertension, fatty liver — bring this framework to your next medical appointment. Many of my clients have come off pharmaceuticals they were told were permanent. The conversation that produces that outcome starts with a patient who has the framework. It almost never starts with the doctor.
You have the framework now. The work is yours.
What’s coming next
This concludes the four-part diabetes series. The next series — coming later this year — will be the honest accounting of every major diabetes drug class. What metformin actually does and doesn’t do. What the SGLT2 inhibitors actually accomplish for the liver and the cardiovascular system. What the GLP-1 reality looks like now that we have phase 3 MASH data and FDA approval for liver disease treatment. Who genuinely benefits from each class, who doesn’t, and where lifestyle change still wins on durability.
The drugs are tools. They’re not the cure. But understanding what each one actually does — beyond the marketing and beyond the contrarian dismissal — is essential for anyone navigating a treatment plan with their physician. That’s what the next series will be for.
This concludes the four-part series on type 2 diabetes.
- Pre-Diabetes Is Not the Early Stage of Type 2 Diabetes. It’s the Late Stage of Insulin Resistance.
- The Twin Cycle: What Actually Causes Type 2 Diabetes.
- The ACCORD Trial and the GLP-1 Trap: Why the Drugs Aren’t the Answer.
- The Cure: How Type 2 Diabetes Is Reversed. (this post)
If this series has been useful to you, the single most consequential thing you can do with it is forward it to someone in your life who’s been diagnosed with type 2 diabetes within the last six years. The window matters. The conversation has to start somewhere. Send the series. Help them have it.
A note on what this is and isn’t
This series is educational content built from peer-reviewed research, clinical trial data, and my work as a nutrition and fitness coach. It is not medical advice. I am not a physician. The information here is designed to give you the framework and the questions to bring to your own medical team — not to replace that team.
Specifically:
Do not stop or adjust any prescription medication based on what you’ve read here. Sudden cessation of insulin, sulfonylureas, blood pressure medications, or other prescriptions can be dangerous. Any medication change must happen in coordination with your prescribing physician.
Find a physician who works on remission, not just management. If your current doctor isn’t willing to engage with the framework in this series, that’s important information. A second opinion is reasonable. Preventive cardiology practices, functional medicine practitioners, and physicians familiar with the DiRECT, ReTUNE, or Virta protocols are good starting points.
Individual results vary. Trial data describes populations. You are an individual with your own medical history, comorbidities, medication regimen, and personal circumstances. The general framework in this series will not be the right framework for every reader. Use your judgment. Talk to your team. Ask the questions.
If you experience symptoms of hypoglycemia — shakiness, sweating, confusion, rapid heartbeat, severe hunger, dizziness — while making dietary changes on glucose-lowering medication, this is a medical emergency. Consume fast-acting glucose immediately and contact your physician. This is the single most important safety point in the entire series.
The goal of this work has always been informed patients, not stopped medications. The medications come off as a byproduct of metabolic improvement, under medical supervision, when the underlying disease state no longer warrants them. That’s the model. That’s what the trial data supports. That’s what the work looks like in practice.
You have the framework. The work is yours. The medical team is theirs. The combination is what produces the outcome.
One BadAss BITCH 